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Background: We have previously shown that lymphopenia and monocytopenia at 2–3 months post-allogeneic
haematopoietic cell transplant (HCT) is associated with poor survival in recipients of both myeloablative and
reduced intensity conditioning regimens. It is not known whether the graft leukocyte content has a role in early
lymphocyte and monocyte recovery following allogeneic T-cell replete peripheral blood HCT.
Methods: Haematologic recovery data, including absolute lymphocyte and monocyte counts (ALC and AMC,
respectively) at day +15, +30, +60, and +100, and outcomes data were pooled from two prior independent cohorts,
and parameters were correlated with leukocyte graft content in those individuals receiving peripheral blood
progenitor cell grafts. 216 consecutive patients from 2001–2010 were included in the analysis.
Results: Neither infused allograft lymphocyte, monocyte, granulocyte, nor CD34+ cell number per kilogram
recipient body weight correlated with haematologic recovery parameters or overall survival in this cohort.
Prognostic factors for overall survival based on multivariate analysis were as expected from the results of the
previous independent cohorts and included severity of chronic GVHD (p < 0.001), development of post-transplant
relapse (p = 0.001), day +60 AMC > 0.3 x 109 cells/L (p = 0.0015), and day +100 ALC > 0.3 x 109 cells/L (p < 0.001).
Low monocyte and lymphocyte counts at the day +60 and day +100 time points were significantly associated with
acute GVHD and/or CMV viraemia.
Conclusions: This study suggests that graft cell count does not influence post-transplant monocyte and lymphocyte
recovery following T-cell replete allogeneic peripheral blood HCT. Post-transplant complications such as acute
GVHD and/or CMV viraemia negatively influenced monocyte and lymphocyte recovery, and hence the survival.
Further studies aimed at understanding the mechanisms behind sustained lymphopenia and monocytopenia
post-transplant are needed.
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The development of cytopenias after initial donor haem-
atopoietic cell engraftment is a risk factor for poor trans-
plant outcomes [1]. We have previously identified that
significant lymphopenia and monocytopenia, defined as
an absolute lymphocyte or monocyte count (ALC and
AMC, respectively) of < 0.3 × 109 cells/L at day +100
post-transplant, are independent risk factors for inferior
survival [2,3]. The objective of this study was to deter-
mine whether the leukocyte content of the T-cell replete
peripheral blood haematopoietic cell allograft is respon-
sible at least in part for post-transplant ALC and AMC
recovery in the first 100 days post-HCT, or whether the
secondary cytopenias predominantly reflect the detri-
mental impact of transplant complications on graft func-
tion and immune reconstitution. Allograft monocytes
have previously been shown to suppress T-cell prolifera-
tion in a dose-dependent fashion, with an associated de-
crease in acute GVHD risk in retrospective series [4,5]. A
previous prospective study of allograft leukocyte content
did not identify an association between pot-transplant
survival and lymphoid and myeloid reconstitution [6],
although monocytes were not analyzed in that study.
Clarification of the role of infused graft monocytes in
controlling acute graft versus host disease (GVHD)
could lead to modification of apheresis strategies or




Patients included in this analysis were pooled from our
prior two reports, a myeloablative (MA) cohort of 135
patients, and a reduced intensity (RIC) cohort of 118 pa-
tients [2,3]. Patients receiving bone marrow grafts were
eliminated from the analysis (24 from the MA and 8
from the RIC cohorts). Of the 221 remaining patients, 5
did not have complete data on graft leukocyte subsets,
leaving 216 consecutive patients available for analysis in
this study. All patients underwent allogeneic HCT from
2001-2010 at Mayo Clinic in Rochester, MN. All patients
gave written consent to use their medical records for re-
search. No patients were lost to follow-up. Approval for
the retrospective review of these records was obtained
from the Mayo Clinic Institutional Review Board and
was in accordance with US federal regulations and the
Declaration of Helsinki.
Determination of allograft leukocyte subset content
Lymphocyte, granulocyte, and monocyte content was
obtained prior to 11/13/2009 by manual differentials
using standard clinical criteria. After that time, flow
cytomtery using a BD FACSCalibur (Becton Dickinson
Biosciences, San Jose, California) was used to determineproduct content using forward and side scatter charac-
teristics of the lymphocyte, granulocyte and monocytes.
This method was validated in the laboratory and proven
to be consistent with prior results with manual differen-
tials. CD34 positive cell content was determined by flow
cytometry using the Stem-Kit (Beckman Coulter, Brea,
California) in combination with BD TruCount beads in a
lab developed test. All data were obtained from results
generated during routine clinical care.
End points
The primary end point of the study was to determine the
association of allograft leukocyte content on overall sur-
vival, post-transplant complications, and peripheral blood
ALC and AMC at day +15, +30, +60, and +100 post-
HCT. Enumeration of leukocyte subsets, including CD34+
cells, granulocytes, monocytes, and lymphocytes was per-
formed on fresh allografts after apheresis and prior to
transplant per institutional standard operating procedures.
The ALC and AMC were obtained by review of the med-
ical records of the complete blood cell count (CBC) [7] at
day +15, +30, +60, and +100 post-HCT.
Prognostic factors and survival
The prognostic factors evaluated in the study included:
graft leukocyte subset content, age at transplant, disease
status at transplant, related versus unrelated donor stem
cell source, degree of HLA-matching, treatment of
confirmed, quantifiable CMV viraemia by PCR with
ganciclovir or valganciclovir prior to day +100, presence/
grade of acute GVHD based upon the Glucksberg-Seattle
grading system [8], presence/severity of chronic GVHD
based upon NIH consensus criteria [9] and ALC and
AMC recovery post-HCT. Overall survival (OS) was
defined from the time of transplant to last follow-up or
death due to any cause.
Statistical analysis
OS estimates were determined using the approach of
Kaplan and Meier [10]. Differences between survival
curves were tested for statistical significance using the
2-tailed log-rank test. The Cox proportional hazard
model was used for univariate analysis of continuous
variable as well as multivariate analysis. Graft leukocyte
subsets were analyzed as continuous variables. Dividing
the graft subsets in half, in tertiles, or in quartiles, did
not change the results of the analysis (not shown). Asso-
ciations between categorical variables were determined
by Fisher’s exact test. Correlations between continuous
variables were determined by Spearman’s rho. Because
of multiple comparisons with the correlation analysis, a
Bonferroni correction was applied. All p-values repre-
sented were two-sided and statistical significance was
declared at p< 0.05.
Table 1 Patient characteristics and univariate survival analysis
Characteristic Patients (N = 216) % Univariate OS p
Year of transplant, median (range) 2007 (2000–2010) 0.03
Age, median (range) 51 (19–71) 0.44
Sex Male 99 46% 0.42
Female 117 54%
Conditioning FM (RIC) 109 50% 0.55
MA (Cy/TBI or Bu/Cy) 107 50%









Donor type Related 186 86% 0.47
Unrelated 30 14%
Match Degree Complete match 204 94% 0.92
1 allele or antigen mismatch 10 5%
2 allele or antigen mismatch 2 1%
Disease status at transplant Complete remission 126 58% 0.003
Not in remission 90 42%
CD34+ cells x 10(6)/kg infused, median (range) 6.0 (1.85 - 17.06) 0.74
Monocytes x 10(6)/kg infused, median (range) 250 (25.7 - 1,139) 0.27
Lymphocytes x 10(6) infused, median (range) 419 (3.04 - 1,530) 0.92
Granulocytes x 10(6) infused, median (range) 166 (5.3 - 1,038) 0.4
Days to ANC 500, median (range) 15 (3–101) 0.83
Days to platelet 50,000 median (range) 19 (0–393) 0.67









CMV reactivation Yes 72 33% 0.15
No 144 67%
Relapse Yes 47 22% 0.002
No 169 78%
ALC day +15 > 0.3 x 10(9)/L 97 45% 0.017
AMC day +15 > 0.3 x 10(9)/L 142 66% 0.94
ALC day +30 > 0.3 x 10(9)/L 183 85% <0.001
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Table 1 Patient characteristics and univariate survival analysis (Continued)
AMC day +30 > 0.3 x 10(9)/L 193 89% 0.001
ALC day +60 > 0.3 x 10(9)/L 172 80% 0.0004
AMC day +60 > 0.3 x 10(9)/L 138 64% <0.001
ALC day +100 > 0.3 x 10(9)/L 158 73% <0.001
AMC day +100 > 0.3 x 10(9)/L 139 64% <0.001
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Patient characteristics
Patient characteristics are described in Table 1. The me-
dian age of the cohort was 51 years with a slight female
predominance (54%). The underlying disease was AML
in 53%. All patients received consistent supportive care
including calcineurin inhibitor-based graft-versus-host
disease prophylaxis. The majority of the stem cell grafts
were derived from fully-matched related donors (86%).
Over half of patients underwent allogeneic HCT in first
remission (58%). Median overall survival for the entire
cohort was 26.6 months. 109 patients died at the time of
analysis, and the median follow up for surviving patients
was 50.1 months. 68 patients (31%) in this cohort died
from non-relapse complications, and 41 patients (19%)
died from relapse.
Allograft leukocyte content, ALC and AMC recovery, and
survival: Univariate analysis
No graft leukocyte subset was associated with OS as a
continuous variable (Table 1), or divided above/below
the median, or in quartiles (not shown). As expected
from our prior reports, ALC and AMC >0.3 × 109/L wasTable 2 Association of graft leukocytes with clinical
outcomes
Category Cells/kg p












Relapse Graft monocytes 0.23
Graft lymphocytes 0.51
Graft granulocytes 0.28
Graft CD34+ 0.1associated with improved survival, especially at the day
+30, 60, and day +100 time points. Graft leukocyte sub-
sets were not associated with the development of the
clinical outcomes of acute GVHD, chronic GVHD, CMV
reactivation, or relapse (Table 2). Graft leukocyte subsets
did not correlate with post-transplant ALC or AMC at
any of the time points measured (Table 3).
Multivariate analysis
Multivariate analysis (Table 4) including the parameters
that demonstrated a significant difference in overall
survival in the univariate analysis revealed the follow-
ing independent prognostic factors: severity of chronic
GVHD, development of post-HCT relapse, day +60
AMC, and day +100 ALC. Day +60 monocytopenia oc-
curred in 57 patients and was associated with day +100
lymphopenia (p = 0.05), which occurred in 18 patients.
Association of monocytopenia, lymphopenia, and GVHD
Acute GVHD was associated with day +60 monocy-
topenia (median 0.2 vs. 0.3 × 109/L, p = 0.01) and less
so with day +100 lymphopenia (median 0.5 vs. 0.6 × 109/L,
p = 0.05).Table 3 Associated variables
Variable By variable Spearman’s rho p
D15AMC D15ALC 0.65 <.0001
Graft Mono/kg Graft Lymph/kg 0.61 <.0001
Graft Gran/kg Graft Mono/kg 0.53 <.0001
D100ALC D60ALC 0.56 <.0001
D30AMC D30ALC 0.50 <.0001
Graft Gran/kg Graft Lymph/kg 0.48 <.0001
D100AMC D100ALC 0.50 <.0001
D30ALC D15ALC 0.40 <.0001
D60ALC D30ALC 0.38 <.0001
D100AMC D60AMC 0.38 <.0001
D60AMC D60ALC 0.36 <.0001
D100ALC D30ALC 0.30 0.014
D60ALC D15ALC 0.28 0.02
D30AMC D15ALC 0.27 0.02
D100ALC D15ALC 0.28 0.03
D100AMC D15AMC 0.28 0.05
Only statistically significant relationships are shown
Table 4 Multivariate analysis
RR 95% CI P
cGVHD severity <0.001
mild vs. none 0.3 0.12 - 0.64
mild vs. moderate 0.88 0.32 - 2.3
mild vs. severe 0.26 0.1 - 0.68
Relapse 2.7 1.64 - 4.35 0.0001
D60 AMC > 0.3 x 10(9)/L 0.44 0.26 - 0.73 0.0015
D100 ALC > 0.3 x 10(9)/L 0.22 0.11 - 0.46 <0.001
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CMV reactivation was strongly associated with day +60
monocytopenia but no other longitudinal haematopoi-
etic parameter in this study (median 0.1 vs. 0.4 × 109/L
for those who did vs. did not receive treatment for CMV
reactivation prior to day +100, p < 0.001).
Association of monocytopenia, lymphopenia, and relapse
Day +100 ALC was lower in patients who experienced
subsequent relapse of their underlying malignancy
(0.3 vs. 0.6 × 109/L, p = 0.03). No other associations be-
tween cytopenias and transplant complications were iden-
tified at the other time points studied.
Association of monocytopenia, lymphopenia, overlapping
transplant complications, and long term survival
Recognizing that patients can have multiple complications
at once, we constructed a Venn diagram that depicts over-
lapping of post-transplant complications (acute GVHD,
CMV reactivation, and relapse) in patients with the most
prevalent prognostic laboratory value in this series, day +60
monocytopenia (Figure 1). Over 90% of the 57 patients with
day +60 monocytopenia had concurrent acute GVHD and/
or CMV reactivation (Figure 1). Importantly, day +60Figure 1 Venn diagram of patients experiencing post-transplant
complications in association with day +60 monocytopenia.monocytopenia in the setting of acute GVHD and CMV
reactivation negatively impacted survival (Figure 2). In
an effort to understand additional risk factors for these
secondary cytopenias, increasing age showed a trend to-
ward failure to achieve the 0.3 × 109/L AMC threshold
at day +60 (p = 0.07), but no other host or graft factors
could be identified at this or other time points for ALC
or AMC. All 2 year survivors (81 patients, 38%) met the
predetermined either day +60 AMC or day +100 ALC
threshold of >0.3 × 109/L, and majority of them met both
(Figure 3). Of the 55 patients who met both ALC and
AMC thresholds but did not survive 2 years, 41 of them
(75%) died from relapsed disease. 39 patients who did not
meet the ALC or AMC thresholds did not survive 2 years.
Is there an optimal cellular composition of allografts?
In this report, we demonstrate that post-allogeneic HCT
lymphopenia and monocytopenia in the intermediate re-
covery phase post-HCT are related to early complica-
tions rather than allograft leukocyte content. This is in
contrast to the autologous transplantation setting, where
the autograft lymphocyte and monocyte content directly
correlates with post-transplant lymphocyte and monocyte
recovery and survival [11-14]. In our cohort, we identified
age as a possible contributor to post-transplant secondary
cytopenias, as have others [1]. Similarly, a recent analysis
of lymphocyte populations in patients enrolled in Blood
and Marrow Transplant Clinical Trials Network trial 0302
also identified that patients responding to therapy for
acute GVHD, regardless of the treatment arm, had a less
substantial decline in peripheral blood CD45+ leukocytes
compared to those who were not responding to treatment
[15]. However, other studies have identified a correlation
with various components of allografts and post-HCT
hematopoiesis and outcomes [6,16-19]. It is possible
that more refined subsets other than simple granulocyte,
monocyte, and lymphocyte content of the graft relates to
outcomes. Lonial et al recently identified that granulocyte-
macrophage colony stimulating factor given concomi-
tantly with G-CSF mobilized fewer plasmacytoid dendritic
cells and T cells from HLA-matched sibling donors, lead-
ing to more rapid immunologic recovery but with no
overall impact on survival [20].
What are the mechanisms behind post-HCT cytopenias?
Medications, especially steroids and ganciclovir, are well
known to cause cytopenias, predominantly lymphopenia
with the former and neutropenia with the latter, although
such side effects are not universal among HCT recipients.
Efforts to better understand other mechanisms of post-
transplant cytopenias are ongoing, including the potential
role of pro-inflammatory cytokines such as tumor-necrosis
factor-alpha (TNF-α) and interferon-gamma (IFN-γ) on the
suppression of hematopoiesis occurring after HCT. As
Figure 2 Kaplan Meier estimate of patients experiencing post-transplant complications in association with day +60 monocytopenia.
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tioning regimens administered prior to HCT lead to dam-
age of host tissues, production of pro-inflammatory
cytokines [i.e. TNF-α, interleukin 1 and 6 (IL-1, IL-6)] and
other inflammatory stimuli (i.e. lipopolysaccharide, LPS),
which then promotes the activation of antigen-presenting
cells (APCs) involved in the pathogenesis of acute GHVD
[21]. Pro-inflammatory cytokines, and specifically TNF-α
and IFN-γ, have also been implicated in the pathogenesis ofFigure 3 Two year survival in association with day +60 AMC
and day +100 ALC thresholds.primary bone marrow failure states and haematopoietic
stem cell suppression [22-26] and the inflammatory state
that develops in the setting of post-HCT complications
such as GVHD or infections. Why some patients are more
susceptible to secondary cytopenias and marrow suppres-
sion, as well as other post-HCT complications, is unclear
but may relate to patient-specific and disease-specific differ-
ences such as specific single-nucleotide polymorphisms as
well as non-HLA genetic variation within the major histo-
compatibility complex [27-31] or other mechanisms. The
role of these patient and disease variables, as well as the
contribution of cytokine fluctuations [32], on post-HCT cy-
topenias, immunologic reconstitution, as well as post-HCT
outcomes, is an area of active investigation and remains to
be fully elucidated.
Limitations
Our study has several limitations. This retrospective co-
hort was transplanted at a single institution, where the
majority of transplants were from HLA-matched sibling
donors. These results may not be applicable to the min-
imal intensity setting, nor to cohorts where the majority
of grafts are derived from unrelated or alternate donors,
although early lymphocyte recovery has previously
shown to be prognostic after T-cell depleted grafts, [33]
umbilical cord blood grafts [34], and unmanipulated
haploidentical grafts [35]. In the latter study, a lympho-
cyte recovery threshold of >0.3 × 109/L at day +30 was
also shown to significantly impact OS, PFS, relapse and
TRM and was significantly correlated with CD3+ T cells
in the allograft [35]. Additionally, detailed flow cytomet-
ric phenotyping of cellular subsets was also not per-
formed (e.g., graft regulatory T cells [36]), and all data
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clinical care. Therefore to confirm the findings of this
study, a larger retrospective study using CIBMTR data-
base of over 30,000 HCT procedures is being performed.
While confirmatory studies are underway, this study
suggests that both monocytopenia and lymphopenia at
2-3 months post-HCT are emerging predictors of poor
survival. Development of these secondary cytopenias ap-
pears to be related to the development of acute GVHD
and CMV viraemia and possibly recipient age, as op-
posed to graft leukocyte content or other established
clinical factors.
Although allogeneic transplantation offers the only
curative option for many advanced and high-risk
haematologic malignancies, the costs associated with
the procedure have come under increased scrutiny
($96,000 -$204,000 in the first year in 2012) [37]. The
single biggest driver of expenditure is the length of in-
patient hospital stay [37]. The role of cytopenias is par-
ticularly important given its associations with acute
GVHD and infections, both of which frequently necessi-
tate hospital admissions [38]. Patients with secondary cy-
topenias may be those requiring increased resource
utilization. Therefore, this group of patients may be ap-
propriate for early, novel interventions to facilitate haem-
atologic and immune recovery. If our findings are
confirmed in larger studies, it would provide a rationale
for conducting clinical trials to proactively enhance lym-
phohaematopoietic recovery following allogeneic HCT.
Conclusions
In our cohort of 216 recipients of peripheral blood pro-
genitor cell allografts, we did not identify a clear role of
graft monocyte or other cellular component as being
predictive of GVHD, relapse, or survival. Post-transplant
lymphopenia and monocytopenia were predominantly
associated with acute GVHD and preemptive therapy for
CMV viraemia. In patients experiencing these complica-
tions but with adequate lymphocyte and monocyte
counts at the day +60 and day +100 time points, long
term survival did not appear to be negatively impacted.
Further studies aimed at understanding which patients
are most vulnerable to developing secondary cytopenias,
and how to improve immune recovery in the face of
these complications, are needed.
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